share_log

HC Wainwright & Co. Maintains Buy on Viracta Therapeutics, Lowers Price Target to $4

Benzinga ·  Jan 5 19:17

HC Wainwright & Co. analyst Robert Burns maintains Viracta Therapeutics (NASDAQ:VIRX) with a Buy and lowers the price target from $10 to $4.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment